Liver International
Liver International
5 years ago

On-treatment changes of liver stiffness at week 26 could predict 2-year clinical outcomes in HBV-related compensated cirrhosis

Jidong Jia, Lijuan Huo, Tao Han, Huiguo Ding, Yongpeng Chen, Jilin Cheng, Yuanyuan Kong, Yameng Sun, Hai Li, Xuqing Zhang, Anlin Ma, Shanshan Wu, Hui Zhang, Xiaojuan Ou, Wei Jiang, Xiaoning Wu, Shibin Xie, Wen Xie, Hongxin Piao, Bo Feng, Xiaoyuan Xu, Lungen Lu, Jia Shang, Jialing Zhou, Hong You
Background & Aims It is unclear whether liver stiffness measurement (LSM) dynamic changes after anti-HBV treatment could predict the risk of liver related events (LREs), particularly in patients with HBV-related compensated cirrhosis. Methods Treatment-naïve patients with HBV-related compensated cirrhosis were enrolled. All patients were under entecavir-based anti-viral therapy, and followed up every 26 weeks for two years. The association between LSM and LREs were analyzed by Cox proportional hazard model and Harrell C-index analysis. Results A total of 438 patients were included in the study. At the follow-up of 104 weeks, LREs developed in 33/438(7.8%) patients, including 16 episodes of decompensation, 18 HCC and 3 deaths. The median LSM remained high from 20.9, 18.6, 20.4 to 20.3 Kpa at week 0, 26, 52 and 78 among patients with LREs, whereas the LSM decreased from 17.8, 12.3, 10.6 to 10.2 Kpa in patients without LREs, respectively. Percentage changes of LSM at 26 weeks from baseline was significantly associated with LREs (excluding 11 cases occurred within the first 26 weeks), with a crude hazard ratio of 2.94(95% CI: 1.73-5.00) and an albumin-adjusted hazard ratio of 2.47(95% CI: 1.49-4.11). The Harrell C-index of these two models for predicting 2-year LREs were 0.68(95% CI: 0.56-0.80) and 0.75(95% CI: 0.65-0.85), respectively. Nomograms were developed to identify individuals at high risk for point-of-care application. Conclusions Dynamic changes of LSM alone, or combined with baseline albumin, could predict LREs in patients with HBV-related compensated cirrhosis during anti-viral therapy. This article is protected by copyright. All rights reserved.

Publisher URL: http://onlinelibrary.wiley.com/resolve/doi

DOI: 10.1111/liv.13623

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.